Clinical trials: BCG Vaccine
Side Effect of Drug
NORTH-REG Dwell-Time Study
Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations.
- Trial name
- NCT04701151
- Testing
- Bacillus Calmette Guerin
- Where
- 11 sites in Denmark, Iceland and 1 more
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Jørgen Bjerggaard Jensen
Tuberculosis
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection
Phase I, randomized, double blinded, Placebo-controlled, immunogenicity and dose-range finding study of AERAS-404 in Bacille Calmette-Guerin (BCG) healthy adult male and sterile females.
- Trial name
- NCT02066428
- Testing
- AERAS-404
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Aeras
Tuberculosis
Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle & Syringe
The study is designed to test the hypothesis that BCG administration via jet injector will produce a comparable immune response and that there will be no significant differences in safety or reactogenicity between BCG…
- Trial name
- NCT01742364
- Testing
- Bioject ID Pen, Needle and syringe
- Where
- South Africa
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- PATH
COVID-19, Non-specific Effects of Vaccines
Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
Background: The COVID-19 pandemic challenges the available hospital capacity, and this will be augmented by absenteeism of healthcare workers (HCW).
- Conditions
- COVID-19, Non-specific Effects of Vaccines, Morbidity, Absenteeism
- Trial name
- NCT04373291
- Testing
- BCG-Denmark, Saline
- Where
- Denmark
- Volunteers
- 1,293 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Tuberculosis
Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon
Filarial nematodes modulate the host immune response to promote regulatory and T helper type 2 immune responses, which were shown to influence concomitant infections.
- Trial name
- MAP-TB (NCT04547738)
- Testing
- TB treatment according to national guidelines
- Where
- Cameroon
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Healthy
A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.
A pilot study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older adults.
- Trial name
- NCT04507126
- Testing
- Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
COVID-19
The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines
Clinical trial with randomized allocation in two arms (BCG vaccine versus placebo) of volunteers at risk but not yet infected nor vaccinated against SARS-CoV-2.
- Trial name
- SARS-CoV-2 (NCT05507671)
- Testing
- BCG (Bacillus Calmette-Guérin) vaccine
- Where
- 4 sites in Brazil
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Tuberculosis Infection, Tuberculosis
BCG Revaccination in Children and Adolescents
Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection.
- Trial name
- BRiC (NCT05330884)
- Testing
- BCG vaccine, Oral Chemoprophylaxis
- Where
- India
- Volunteers
- 9,200 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Infant Morbidity, Infant Mortality
BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Studies in low-income countries show that vaccines can have important non-specific effects on other infections. Live BCG vaccine can train the immune system and reduce susceptibility to unrelated infections.
- Conditions
- Infant Morbidity, Infant Mortality, Non-Specific Effects of Vaccines, BCG
- Trial name
- BCG2-DTP3 (NCT07005726)
- Testing
- BCG Vaccine
- Where
- Guinea-Bissau
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
HIV Infections, Neonatal Infection
Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
Maternal infections affect the basal immune status of neonates. One of the possible mechanism is the fetomaternal microchimerism, in which some cells and active substances are exchanged bi-directionally between maternal and fetal…
- Conditions
- HIV Infections, Neonatal Infection, LTBI - Latent Tuberculosis Infection, Immune Tolerance
- Trial name
- IMMUNEO (NCT03383211)
- Testing
- RNAseq
- Where
- 2 sites in Moldova
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- George Washington University
Non Specific Effects of Vaccine, Bacillus-Calmette-Guerin
Low Birth Weight Follow-up
The Randomized Control Trail included 4,172 low-birth weight children between February 2008 and September 2013 in Bissau. The children who were included in the RCT and who are living in the Bandim Health Project study area will…
- Conditions
- Non Specific Effects of Vaccine, Bacillus-Calmette-Guerin, Low Birth Weight, Maternal Immunisation
- Trial name
- NCT03020147
- Where
- Guinea-Bissau
- Volunteers
- 1,258 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Mycobacterium Tuberculosis Infection
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation)…
- Trial name
- VPM1002 (NCT04351685)
- Testing
- VPM1002, BCG SII
- Where
- 12 sites in Gabon, Kenya and 3 more
- Volunteers
- 6,940 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Tuberculosis
Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection
The purpose of this study is to demonstrate the efficacy of Bacille Calmette Guerin (BCG) revaccination against sustained Mycobacterium tuberculosis infection versus placebo in previously BCG vaccinated QuantiFERON®-TB Gold Plus…
- Trial name
- NCT04152161
- Testing
- BCG vaccine SSI
- Where
- 5 sites in South Africa
- Volunteers
- 1,836 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
TB
Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine
Tuberculosis (TB) kills about three million people annually. It is estimated that one third of the world's population are latently infected with Mycobacterium tuberculosis (M.tb).
- Trial name
- NCT00654316
- Testing
- BCG
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Alzheimer Disease, Late Onset
BCG and Plasma Amyloid in Non-Demented Adults
BCG vaccination, the most widely used vaccination in the world, is used to reduce risk of tuberculosis infection; it is used for other mycobacterial infections as well, benefiting leprosy and Buruli ulcer.
- Trial name
- NCT04449926
- Testing
- Bacillus of Calmette and Guerin (BCG)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Mindful Diagnostics and Therapeutics, LLC
TB
Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines
This study is preliminary to proving that this vaccine could protect against tuberculosis in humans. Although there is no proven data to show that infants will benefit directly from participation in this study by being protected…
- Trial name
- NCT00480454
- Testing
- MVA 85A
- Where
- The Gambia
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously
This is a phase I study to test the immunogenicity of a recombinant vaccine based on Modified Vaccinia Ankara (MVA) expressing the antigen 85A (from Mycobacterium tuberculosis).
- Trial name
- NCT00427453
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route
This is a phase I trial to compare the safety and immunogenicity of candidate TB vaccine MVA85A administered by the aerosol inhaled route and the intradermal route in healthy BCG-vaccinated adult subjects.
- Trial name
- NCT01497769
- Testing
- Aerosol inhaled MVA85A, Intradermal MVA85A
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
BCG, COVID-19
Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers
In Mexico the total number of confirmed cases of COVID-19 is 232, 000 and 28,510 deaths. Health workers are at high risk of COVID-19 infection. Their absence from work dramatically limits the ability to contain the disease.
- Conditions
- BCG, COVID-19, SARS-CoV2, Corona Virus Infection
- Trial name
- NCT04461379
- Testing
- BCG vaccine
- Where
- Mexico
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
BCG Vaccination Reaction
BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects .
Study of BCG Vaccination scars of under five years old children . Estimation of the frequency of children without BCG scar after BCG vaccine . Evaluation of factors which may affect scar formation .
- Trial name
- bcgscars (NCT03548233)
- Testing
- bcg vaccine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University